

# CURES WITHIN REACH RESEARCHER SPOTLIGHT: A BEACON OF HOPE FOR CHILDREN WITH HEARING LOSS

In 2021, Cures Within Reach began funding **Dr. Joseph Rower** at the **University of Utah** to support a Phase I clinical study to associate valganciclovir exposures with immune responses and hearing outcomes in pediatric congenital cytomegalovirus (cCMV) patients.

Dr. Rower is an expert in **clinical pharmacology**, with specialties in pharmacometric and statistical modeling, and bioanalytical assays. A significant portion of his research has been focused on antiviral drugs. He has a deep interest in pediatrics and has dedicated a share of his research efforts to revolutionizing the clinical care of children by analyzing the impact of age on pharmacokinetic-pharmacodynamic relationships.

His professional goal is to develop a deeper understanding of the connection between clinical outcomes and pharmacokinetics to improve patient care through personalized medicine.



## PROFILE

- Dr. Joseph Rower is a Research Assistant Professor in the Department of Pharmacology and Toxicology.
- Dr. Rower completed his PhD training at the University of Colorado Anschutz Medical Campus.

## CWR FUNDING

- A \$50,000 **Phase I clinical study** is evaluating valganciclovir exposures in pediatric cCMV patients.
- Dr. Rower and this trial represent two of Cures Within Reach's communities:
  - **Rare Diseases**
  - **Pediatrics**

